Editorial: Advances in novel drugs and targets for hepatic and gastrointestinal diseases.
作者信息
Ngowi Ebenezeri Erasto, Gao Yong, Yang Xiaoying, Qiao Aijun
机构信息
Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, Guangdong Province, China.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
出版信息
Front Pharmacol. 2024 Jan 15;15:1364290. doi: 10.3389/fphar.2024.1364290. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Advances in novel drugs and targets for hepatic and gastrointestinal diseases.社论：肝脏和胃肠道疾病的新型药物及靶点研究进展
Front Pharmacol. 2024 Jan 15;15:1364290. doi: 10.3389/fphar.2024.1364290. eCollection 2024.
2
Editorial: Insights in Gastrointestinal and Hepatic Pharmacology: 2021.
Front Pharmacol. 2022 Apr 5;13:890212. doi: 10.3389/fphar.2022.890212. eCollection 2022.
3
Editorial: Herbal medicines for gastrointestinal and hepatic diseases - novel pharmacological and toxicological approaches, Volume I.社论：用于胃肠和肝脏疾病的草药——新的药理学和毒理学方法，第一卷
Front Pharmacol. 2023 Jul 7;14:1157229. doi: 10.3389/fphar.2023.1157229. eCollection 2023.
4
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.药物洞察：分子靶向药物在癌症治疗中的胃肠道和肝脏不良反应
Nat Clin Pract Oncol. 2008 May;5(5):268-78. doi: 10.1038/ncponc1087. Epub 2008 Mar 18.
5
Editorial: Cancer of gastrointestinal tract: Novel insight into the molecular mechanisms related to inflammation and therapeutic targets.社论：胃肠道癌症：对与炎症及治疗靶点相关分子机制的新见解
Front Pharmacol. 2022 Aug 30;13:970491. doi: 10.3389/fphar.2022.970491. eCollection 2022.
6
Editorial: Advances in the potential treatments of gastrointestinal and liver diseases: addressing the public health burden.社论：胃肠和肝脏疾病潜在治疗方法的进展：应对公共卫生负担
Front Pharmacol. 2023 Jul 13;14:1253069. doi: 10.3389/fphar.2023.1253069. eCollection 2023.
7
Psychopharmacology in patients with hepatic and gastrointestinal disease.
Int J Psychiatry Med. 1990;20(2):109-39. doi: 10.2190/1WP5-EHFP-9FMQ-QYKM.
8
New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease.靶向常染色体显性遗传多囊肝病和肾病肝囊肿形成的新见解。
Expert Opin Ther Targets. 2020 Jun;24(6):589-599. doi: 10.1080/14728222.2020.1751818. Epub 2020 Apr 19.
9
A network pharmacology approach to investigating the mechanism of Tanshinone IIA for the treatment of liver fibrosis.网络药理学方法研究丹参酮 IIA 治疗肝纤维化的作用机制。
J Ethnopharmacol. 2020 May 10;253:112689. doi: 10.1016/j.jep.2020.112689. Epub 2020 Feb 23.
10
Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy.肝纤维化：治疗靶点与药物治疗进展
Front Cell Dev Biol. 2021 Sep 21;9:730176. doi: 10.3389/fcell.2021.730176. eCollection 2021.
Zotero 插件